Northern Trust’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Northern Trust’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12	Closed	-$4K	–	4768
2022 Q2	$4K	Hold	12	–	–	﹤0.01%	4732
2022 Q1	$7K	Hold	12	–	–	﹤0.01%	4711
2021 Q4	$13K	Hold	12	–	–	﹤0.01%	4735
2021 Q3	$21K	Hold	12	–	–	﹤0.01%	4608
2021 Q2	$35K	Sell	12 -56	-82%	-$276K	﹤0.01%	4521
2021 Q1	$467K	Sell	68 -6	-8%	-$41.2K	﹤0.01%	3833
2020 Q4	$492K	Buy	74 +2	+3%	+$10.5K	﹤0.01%	3732
2020 Q3	$877K	Buy	72 +44	+157%	+$535K	﹤0.01%	3444
2020 Q2	$334K	Buy	28 +15	+115%	+$169K	﹤0.01%	3634
2020 Q1	$130K	Hold	13	–	–	﹤0.01%	3768
2019 Q4	$140K	Hold	13	–	–	﹤0.01%	3873
2019 Q3	$87K	Hold	13	–	–	﹤0.01%	3947
2019 Q2	$92K	Hold	13	–	–	﹤0.01%	3982
2019 Q1	$69K	Hold	13	–	–	﹤0.01%	3993
2018 Q4	$79K	Buy	+13	New	+$62.2K	﹤0.01%	3970

Other funds holding ATXI

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Northern Trust's ATXI Position: Q3 2022 in Review

Northern Trust sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q3 2022, closing a stake of 12 shares — an estimated $4K sold.

Northern Trust first reported a position in ATXI in Q4 2018 and held it in 15 quarters. The position peaked at $877K in Q3 2020. 10 funds tracked by Wall St. Rank hold ATXI as of Q3 2022.

Northern Trust reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Northern Trust sold 12 Avenue Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $4K.
Northern Trust first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2018 and held it in 15 quarters.
Northern Trust's Avenue Therapeutics, Inc. Common Stock position peaked at $877K in Q3 2020.
10 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Northern Trust's 13F filing for Q3 2022, filed 14 Nov 2022.